Metabolic Dysfunction–Associated Steatotic Liver Disease

This review discusses the global clinical burden and consequences of MASLD as a multisystem disease, briefly describing the natural history, pathophysiology, risk stratification, and case finding of the disease. It focuses on the new and promising metabolism-based pharmacotherapies targeting the liver and coexisting cardiovascular–kidney–metabolic conditions of MASLD.